SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending as the market keenly anticipates a pivotal Department of Energy announcement regarding surplus plutonium awards, a key catalyst for its advanced nuclear technology. Bullish sentiment is driven by expectations of government support and institutional accumulation during a perceived oversold period. Conversely, bears emphasize substantial insider selling and ongoing share dilution, raising concerns about the company's valuation given its current lack of commercial revenue.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

EKSO is experiencing significant upward momentum and trading volume following the announcement of a proposed business combination with Applied Digital's cloud division, forming a new AI compute platform, ChronoScale. The community is actively discussing this pivot into AI infrastructure, with many anticipating a substantial short squeeze despite lingering concerns about potential dilution. This move highlights EKSO's transformation into a key player in the rapidly expanding AI sector.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust (SLV) is experiencing significant volatility and trending amid intense community debate. A recent sharp rebound from declines, attributed by many to alleged manipulation via margin calls, is fueling discussion of a potential short squeeze. The market is buzzing with anticipation over imminent silver export restrictions from China, effective January 1st, 2026, which bulls believe will profoundly impact supply and drive prices higher due to rising industrial demand.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending fueled by its highly engaged community, passionately advocating for the "OG meme" narrative of Rage Comics and actively building out an ecosystem with tools like RageMaker and RageGames. This dedicated base expresses strong conviction, viewing RAGE as significantly undervalued and poised for substantial long-term growth as they lead a "return to the memes" within the broader market upswing.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending amidst a persistent downtrend that has frustrated many investors, fueling community discussion around market manipulation and the stock's daily declines. Despite this bearish sentiment, bulls highlight the company's international expansion, AI integration, and a share buyback program as strong long-term catalysts. The market is weighing Hims' direct-to-consumer model and GLP-1 strategy, particularly after the FDA approval of Novo Nordisk's oral weight-loss pill, creating a divide between those seeing a buying opportunity and those questioning its immediate prospects.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending due to significant community debate and anticipation surrounding potential positive announcements at the upcoming CES 2026. While many investors express frustration over recent price declines, a bullish contingent highlights analyst upgrades, institutional buying, and the company's strong fundamentals in agentic AI voice solutions for automotive and restaurant sectors, viewing current levels as a strategic buying opportunity for long-term growth.

BUUU Group Ltd. is a holding company, which operates through its subsidiaries, BU Creation and BU Workshop. Its subsidiaries engage in design, planning and production of face-to-face events, immersive environments and brand-based experiences for clients and venues, including event organizers, consumer brand marketers and retail shopping centers. The company was founded in 2017 and is headquartered in Hong Kong.

BUUU Group Ltd. - Ordinary Shares - Class A

BUUU Group Ltd

BUUU Group Ltd is experiencing extreme volatility and intense speculative trading, driven by comparisons to other high-flying, low-float Chinese stocks. While many traders are actively chasing rapid gains, a significant portion of the community warns of a potential pump and dump scenario, fueling a highly divided discussion.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending following positive Phase 3 trial data for its relacorilant candidate in platinum-resistant ovarian cancer, sparking community debate over market valuation and intense short-seller activity. Investors are also focused on an upcoming regulatory decision for relacorilant in Cushing's syndrome and promising survival data from its ALS program, fueling discussions about the company's long-term growth and potential for a significant short squeeze.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending with high anticipation for multiple imminent FDA decisions, including a PDUFA date for its motion sickness drug, Tradipitant, and an expedited re-review for Hetlioz in jet lag. The community is actively discussing Tradipitant's significant potential in addressing GLP-1 induced nausea, viewing these regulatory catalysts as crucial for a re-rating given the company's improved relationship with the FDA. Investors are keenly watching for outcomes that could lead to considerable stock movement, drawing comparisons to other recent biotech approvals.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

BYTE is trending as its dedicated community fervently discusses its potential as "Grok's AI dog" or "Elon's AI sidekick," positioning it as the "chosen one" within the digital world. The community widely believes "something big is coming" for this AI-themed memecoin, emphasizing its strong "ByteArmy" and its role as the "future of AI" within the Ethereum ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>According to a report, AIG’s competitor, Chubb, approached the firm with an informal offer to acquire it; however, both Chubb and AIG denied the reports.</li><li>Citi maintained its ‘Neutral’ rating on AIG and assigned an $85 price target.</li><li>Piper Sandler raised its price target on the stock to $95 from $88 and maintained an ‘Overweight’ rating.</li></ul>American International Group (<a href="https://stocktwits.com/symbol/AIG">AIG</a>) stock drew investor attention on Monday after Citi analysts noted that merging with another large insurer would not benefit AIG.According to TheFly, Citi analysts wrote in a research note that they expect American International Group (AIG) to continue acquiring more firms rather than being acquired. Citi believes integration and revenue dyssynergies would likely overwhelm any potential cost savings from a large-scale transaction. The firm maintained a ‘Neutral’ rating on the shares, with an $85 price target.Earlier in the month, an Insurance Insider US <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.insuranceinsiderus.com/article/2fpahsm5la3on7eapsfsw/all-topics/m-a/chubb-made-informal-takeover-approach-for-aig?zephr_sso_ott=LTYHsi">report</a> indicated that Chubb had approached AIG with an informal acquisition offer. However, both firms have reportedly <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.insurancenews.com.au/international/aig-not-for-sale-amid-reports-of-rival-s-interest">denied</a> the same, according to Insurance News.&nbsp;In another note, Piper Sandler raised its price target on AIG to $95 from $88 and maintained an Overweight rating. The firm expects favorable weather to mean most insurers will report strong or even stronger-than-expected results, but pricing commentary will likely be more pessimistic.<h2 class="st-heading-2">Expansion Amidst Streamlining Operations</h2>AIG’s CEO, Peter Zaffino, has been streamlining its operations since taking the reins in 2021 by selling its global personal travel business, and continues to make acquisitions and investments to make AIG into a more capital-aligned company.AIG recently announced it will invest around $5 billion in specialty insurer Convex and asset manager Onex Corporation. As part of the deal, AIG acquired a 35% stake in Convex for $2.1 billion. It also said it will acquire a 9.9% ownership stake in asset manager Onex for about $646 million and will also invest up to $2 billion in its investment funds.AIG also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.everestglobal.com/news/news-details/2025/Everest-Announces-Agreement-to-Sell-Retail-Commercial-Insurance-Renewal-Rights-to-AIG/default.aspx">acquired</a> renewal rights to Everest Group’s global retail insurance portfolio for about $2 billion, which will allow AIG to grow its general insurance arm by incorporating Everest’s existing customers.<h2 class="st-heading-2">How Did Stoctwits Users React?</h2>Retail sentiment around AIG trended in “bearish” territory amid “high” message volumes.<figure class="image"><img style="aspect-ratio:633/74;" src="https://news.stocktwits-cdn.com/AIG_PNG_22be5e3e02.webp" alt="Retail sentiment around AIG trended in “bearish” territory amid “high” message volumes" width="633" height="74"></figure>Shares of AIG have surged over 10% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

The AIG (American International Group) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Does Citi Believe AIG Is More Likely To ‘Acquire’ Than Be Acquired?

Citi analysts believe integration and revenue dyssynergies would likely overwhelm any potential cost savings from a large-scale transaction.

Equity

Citi analysts believe integration and revenue dyssynergies would likely overwhelm any potential cost savings from a large-scale transaction.


<ul class="summary-bullets"><li>The stock has seen a slew of bearish calls from Wall Street after PayPal warned earlier this month that it may face “tougher comps” this quarter.</li><li>It also warned that branded checkout growth is projected to be “at least a couple of points slower.”</li><li>JPMorgan, Deutsche Bank, Evercore ISI, and Wells Fargo have issued bearish calls on PayPal this month.</li></ul>PayPal (PYPL) drew heavy retail attention Thursday after Bank of America downgraded the stock, marking another bearish take from Wall Street amid tougher comparables and slowing branded checkout growth.&nbsp;<a href="https://stocktwits.com/symbol/PYPL">PYPL’s stock</a> was among the top trending tickers on Stocktwits. It slid more than 1.7% in pre-market trade, while retail sentiment around the company on the platform remained in ‘bearish’ territory.<h2 class="st-heading-2">Bank of America Joins Wall Street’s Bearish Calls</h2>Bank of America lowered PayPal’s rating to ‘Neutral’ from ‘Buy’ and cut its price target to $68 from $93, as per TheFly. The firm said the company is taking longer than expected to revive growth, which “limits near-term upside.”The firm had expected product innovation and the upgraded checkout experience to drive increased usage of the PayPal button at checkout. Instead, the analyst said that the fourth quarter (Q4) is likely to see a step down in branded checkout growth and that 2026 will be an investment year for the company.<h2 class="st-heading-2">PayPal Lowers Checkout Growth Outlook</h2>Earlier this month, the PayPal management noted that Q4 comparables will be “tougher” than last year, with branded checkout growth projected to be “at least a couple of points slower” than in the third quarter (Q3).&nbsp;It also stated that guidance for Q4 remains “well intact,” according to remarks at UBS’s 2025 Global Technology and AI Conference cited by TheFly.<h2 class="st-heading-2">Other Wall Street Firms Echo Cautious Stance</h2>After PayPal’s comments, JPMorgan downgraded the stock to ‘Neutral’ from ‘Overweight,’ lowering its target to $70 from $85. It described 2026 as a “show-me execution year” where the company faces both upside potential and execution risk.&nbsp;Deutsche Bank’s Nate Svensson followed with a price target cut to $65 from $75 while maintaining a ‘Hold’ rating on the stock, citing similar concerns over branded checkout performance.&nbsp;Evercore ISI also kept its ‘In Line’ rating with a $65 target, highlighting challenges in the Branded Core segment despite growth in Buy-Now-Pay-Later (BNPL) and Pay with Venmo segments. Wells Fargo, on Wednesday, lowered its target to $67 from $74 and kept an ‘Equal Weight’ rating on the stock.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/coinbase-announces-dex-trading-on-solana-can-now-trade-unlisted-spl-tokens/cLIx469REnb">Coinbase Announces DEX Trading On Solana – Users Can Now Trade Unlisted SPL Tokens</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

PayPal logo can be seen at its office in San Jose, California, United States on November 23, 2019. (Photo by Yichuan Cao/NurPhoto via Getty Images)

PayPal Faces Growing Wall Street Pessimism Over Q4 Growth Slump – BofA Latest To Downgrade Stock

Bank of America lowered PayPal’s rating to ‘Neutral’ from ‘Buy’ and cut its price target to $68 from $93, citing slower growth.

<ul class="summary-bullets"><li>SAIC's third-quarter adjusted earnings per share of $2.58 beat analyst estimates of $2.06.&nbsp;</li><li>Revenue for the quarter came in line with estimates at $1.87 billion.&nbsp;</li><li>The company also raised its adjusted diluted EPS guidance to $9.80 to $10.00, up from $9.40 to $9.60 earlier.</li></ul>Science Applications International Corporation (SAIC) shares traded over 16% higher on Thursday following upbeat third-quarter results and improved guidance.The defense and technology company posted adjusted earnings per share (EPS) of $2.58, far beating the analyst consensus of $2.06, according to Fiscal.ai data. Revenue for the quarter was $1.87 billion, in line with estimates, although 6% lower than the same period last year.SAIC also raised its adjusted earnings before interest, tax, depreciation and amortization (EBITDA) guidance to about $695 million, up from between $680 million and $690 million previously. It is also projecting adjusted diluted EPS of $9.80 to $10.00, up from $9.40 to $9.60 reported before."Our third quarter results reflect a 5.6% revenue contraction, slightly ahead of our guidance when adjusting for the approximate 1% headwind from the government shutdown, and strong margins due to continued sound program execution,” said Jim Reagan, SAIC Interim Chief Executive Officer, in the statement.<h2 class="st-heading-2">Against The Odds</h2>SAIC’s stellar performance comes despite the recent government shutdown, which has affected several federal contractors this quarter. About 98% of the company’s total revenues come from government contracts or subcontracts, the company had said earlier in a filing.Its operating income as a percentage of revenues decreased in the quarter compared with the same period last year, which it attributed to executive transition costs related to a contract termination.SAIC also acquired SilverEdge Government Solutions, a provider of technology solutions and products, last month. The company said that the deal enhanced its strategy to provide mission-focused, IP-based solutions and commercial products to its customers.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment surrounding the stock shifted to ‘extremely bullish’ from ‘neutral’ while message volume jumped to ‘extremely high’.<figure class="image"><img style="aspect-ratio:1276/158;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_04_at_9_01_20_PM_png_3582235eb8.webp" alt="Stocktwits retail sentiment shifted to ‘extremely bullish’ from ‘neutral’ and message volume jumped to ‘extremely high’." width="1276" height="158"></figure> SAIC shares have lost over 9% this year.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/wedbush-backs-snowflake-after-q3-print-suggests-buying-the-dip/cLILyrXRESt">Wedbush Backs Snowflake After Q3 Print, Suggests Buying The Dip</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

AeroVironment exhibited during the Defense Expo Korea 2022, held at KINTEX (Korea International Exhibition and Convention Center) on September 21, 2022 in Goyang city, Gyeonggi, South Korea.  (Photo by Chris Jung/NurPhoto via Getty Images)

SAIC Stock Surges Post Upbeat Q3 Earnings, Improved Guidance

The defense and tech company’s adjusted earnings per share of $2.58 beat analyst estimates by over $0.50. 

<ul class="summary-bullets"><li>Kroger reported Q3 revenue of $33.9 billion, up 1% from the same period last year, missing analyst estimates of $34.2 billion.&nbsp;</li><li>Adjusted earnings per share came in at $1.05, outperforming the $1.03 consensus.&nbsp;</li><li>The company also revised its guidance for identical sales excluding fuel to 2.8% to 3%, down from the previous range of 2.7% to 3.4%.&nbsp;</li></ul> <a href="https://stocktwits.com/symbol/KR">The Kroger Co. </a>(KR) shares traded lower on Thursday morning after the company reported its third-quarter 2025 results, with better-than-expected earnings but revenue missing estimates.Total revenue for the quarter came in at $33.9 billion, up 1% compared to the same period last year. However, this was below analyst estimates of $34.2 billion. The company reported adjusted earnings per share (EPS) of $1.05, beating the $1.03 consensus."We continue to focus on what matters most – serving our customers, running great stores, and strengthening our core business. Our results show we are improving the customer experience and building a strong foundation for long-term growth," said Ron Sargent, Chairman and CEO of Kroger.<h2 class="st-heading-2">Spending Squeeze</h2>The American retailer attributed its business momentum to growth in its e-commerce and pharmacy businesses. Kroger is among the many retailers that are betting big on online sales. “We have now completed our strategic review, which we expect will make our eCommerce business profitable in 2026,” said Sargent.However, the supermarket brand has been under pressure from lowered consumer spending as well as the government shutdown that led to SNAP (Supplemental Nutrition Assistance Program) food-stamp benefits briefly expiring in November. On Wednesday, Macy’s CEO highlighted how customers remained cautious about spending.<h2 class="st-heading-2">Outlook And Sentiment</h2>While Kroger's latest quarter identical sales excluding fuel rose 2.6%, the company revised its guidance for the same to between 2.8% and 3%, from the previous range of 2.7% and 3.4%. The company, however, increased the lower end of its guidance for the adjusted earnings per share to between $4.75 and $4.80 from the previous range of between $4.70 and $4.80.On Stocktwits, retail sentiment surrounding the stock remained ‘bullish’ while message volume jumped to ‘high’.<figure class="image"><img style="aspect-ratio:1264/155;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_04_at_7_33_37_PM_png_c4e591a35c.webp" alt="Retail sentiment for Kroger remained ‘bullish’ while message volume jumped to ‘high’." width="1264" height="155"></figure>Kroger shares have gained over 10% in the past 12 months.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-trak-stock-rise-10-in-premarket-today/cLILyCORESM">Why Did TRAK Stock Rise 10% In Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

A Kroger grocery store in Atlanta, Georgia. (Photo by: Jeffrey Greenberg/Universal Images Group via Getty Images)

Kroger Stock Trades In The Red As Q3 Revenue Falls Short of Estimates Despite Earnings Beat 

The retailer reported revenue of $33.9 billion which missed analyst estimates, but posted above consensus earnings per share of $1.05.

Buffett's Investing Lessons: What They Mean for ETF Investors

Buffett's final lessons guide ETF investors toward discipline, cash strength and quality picks like SPY, ITOT, VTV and MINT.

<ul class="summary-bullets"><li>4D-150 demonstrated consistent and durable benefits in patients with wet age-related macular degeneration in the study.&nbsp;</li><li>The company is currently enrolling patients into late-stage trials for the drug.</li><li>Enrollment is continuing ahead of initial projections, CEO David Kirn said. &nbsp;</li></ul>4D Molecular Therapeutics (FDMT) announced on Thursday that its experimental drug 4D-150 demonstrated consistent and durable benefits in patients with wet age-related macular degeneration in an early-to-mid-stage trial.Wet age-related macular degeneration (AMD) is an advanced form of macular degeneration where abnormal blood vessels grow in the retina, leak fluid or blood, and cause a rapid decline in central vision. The proliferation and leakage of abnormal blood vessels is stimulated by vascular endothelial growth factor (VEGF), a protein that promotes the growth of new blood vessels. According to 4D, the disease has a high incidence, with 200,000 individuals estimated to be newly diagnosed every year in the U.S. alone.<h2 class="st-heading-2">Study Findings</h2>4D-150 showed maintenance of visual acuity and control of retinal anatomy in the study, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-announces-positive-long-term-data-phase-12-prism-clinical">said</a>. The study also reduced treatment burden as patients maintained a consistent and clinically meaningful reduction in supplemental injections in 6-month intervals following dosing with 4D-150 through up to two years of follow-up, it added.4D-150 was further well tolerated with no new safety or intraocular inflammation findings. The drug is aimed at providing multi-year, and potentially lifelong, sustained delivery of anti-VEGF from the retina with a single, safe, intravitreal injection. Anti-VEGF is a treatment that blocks the action of the vascular endothelial growth factor.The company is currently enrolling patients into late-stage trials for the drug. Enrollment is continuing ahead of initial projections, according to CEO David Kirn.“With the robust PRISM dataset and our APAC region strategic partnership with Otsuka announced last week, we are well positioned for global success in our Phase 3 4FRONT clinical trials, which continue to enroll ahead of initial projections,” he added. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company soared 13% in the pre-market session at the time of writing. On Stocktwits, retail sentiment regarding <a href="https://stocktwits.com/symbol/FDMT">FDMT stock</a> remained within the ‘bullish’ territory, while message volume remained at ‘high’ levels over the past 24 hours.FDMT stock is up 89% this year and approximately 26% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dupont-announces-2-billion-share-buyback-stock-tumble-7-today/cL2t8hLREbz">DuPont Announces $2 Billion Share Buyback: Why Did The Stock Tumble 7% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

FDMT Stock Gains Pre-Market After Positive Study Data For Experimental Drug In Eye Disease

The drug showed maintenance of visual acuity, control of retinal anatomy, and reduction of treatment burden at all time points with up to 2 years of follow-up. 

Payment services applications PayPal and Venmo were both down for some users in the United States&nbsp;on Thursday, according to Downdetector, which tracks real-time outages across thousands of websites, apps, and internet providers.Downdetector showed that 9,597 users in the United States were facing issues with PayPal at 12 p.m. ET, and 8,373 users were having outages on Venmo as of 11:47 a.m. ET.<figure class="image"><a class="st-link-external" href="https://downdetector.com/status/paypal/" target="_blank" rel="noopener noreferrer nofollow"><img style="aspect-ratio:951/588;" src="https://news.stocktwits-cdn.com/Pay_Pal_DD_png_e0280c5766.webp" alt="PayPal DD.png" width="951" height="588"></a></figure>Users on Stocktwits also noted issues regarding logging into PayPal.<stembedurl>https://stocktwits.com/ToRni27/message/632596267</stembedurl>According to Downdetector, 83% of users reported login issues for PayPal, while 10% noted payment-related issues and 6% purchase problems. Shares of PayPal were down nearly 3% in afternoon trading.For Venmo, Downdetector showed that 54% of the users were facing issues on the application and 8% on its website. Meanwhile, 38% reported login issues on Venmo, per Downdetector.<figure class="image"><a class="st-link-external" href="https://downdetector.com/status/venmo/" target="_blank" rel="noopener noreferrer nofollow"><img style="aspect-ratio:955/591;" src="https://news.stocktwits-cdn.com/Venmo_DD_png_721fc24224.webp" alt="Venmo DD.png" width="955" height="591"></a></figure>Venmo was bought by PayPal in 2013. Retail sentiment on PayPal dipped to ‘neutral’ from ‘bullish’ territory a day ago, with message volumes at ‘high’ levels, according to data from Stocktwits.According to a PayPal spokesperson, both PayPal and Venmo experienced a brief service disruption, which has since been resolved.On Monday, Goldman Sachs analyst Will Nance downgraded PayPal to ‘Sell’ from ‘Neutral’ with a $70 price target, according to TheFly. The firm said it believes PayPal will face several transaction margin headwinds in 2026, including interest rate headwinds and the lapping of a reacceleration of its credit products.Goldman said it also sees less visibility for the company's branded checkout reacceleration in the near term, given softer trends in Germany, tariff disruptions in the U.S., and competing wallet form factors. <a href="https://stocktwits.com/symbol/PYPL">Shares of PayPal</a> have declined nearly 23% this year and have lost 17.5% of their value in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/apple-s-eddy-cue-pushes-for-fixing-sports-streaming-as-company-nears-formula-1-rights-deal/ch6pIQER3nx">Apple’s Eddy Cue Pushes For Fixing Sports Streaming As Company Nears Formula 1 Rights Deal</a>Editor's Note: The story has been updated with PayPal's statement regarding the service disruption.

In this photo illustration, a person holds a smartphone displaying the logo of PayPal Holdings Inc. 

Are PayPal, Venmo Down In The US? Here's What Downdetector Shows

Downdetector showed that 9,597 users in the United States were facing issues with PayPal at 12 pm ET, and 8,373 users were having outages on Venmo as of 11:47 am ET.

Shares of Roivant (ROIV) jumped 9% on Wednesday after the company, along with Priovant Therapeutics, announced positive results from a late-stage trial evaluating Brepocitinib in dermatomyositis.Dermatomyositis is a multi-organ idiopathic inflammatory condition that affects approximately 50,000 adults in the U.S. and is characterized by debilitating muscle weakness and skin lesions. No targeted therapies are approved for the condition, and a majority of patients are treated with high-dose oral steroids.Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study, including measurements of skin disease, muscle disease, steroid-sparing effect, and rapidity of onset, the company said.On Stocktwits, retail sentiment around ROIV stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:619/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_17_at_2_05_09_PM_png_94ffd6f84d.webp" alt="ROIV's Sentiment Meter and Message Volume as of 2:05 p.m. ET on Sept. 17, 2025 | Source: Stocktwits" width="619" height="61"><figcaption>ROIV's Sentiment Meter and Message Volume as of 2:05 p.m. ET on Sept. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism that the stock would rally further to $17.<stembedurl>https://stocktwits.com/StockBraker/message/628947861</stembedurl>Another user also cheered the stock’s rally over the past few weeks.<stembedurl>https://stocktwits.com/bbbloo/message/628950392</stembedurl>The company stated that 30mg of Brepocitinib achieved a week 52 mean Total Improvement Score (TIS) of 46.5 compared to 31.2 for placebo. It added that more than two-thirds of patients receiving the Brepocitinib 30 mg dose experienced at least a moderate response, with a TIS equal to or greater than 40, and nearly half experienced a major response, with a TIS equal to or exceeding 60.Furthermore, 42% of Brepocitinib 30 mg patients were able to discontinue steroids altogether, compared to 23% for the placebo, while 62% achieved a steroid dose of 2.5 mg or less per day. The safety profile observed in the study was consistent with that of previous trials, the company stated.The company plans to file for approval of the drug with the U.S. Food and Drug Administration for the treatment of dermatomyositis in the first half of 2026.ROIV stock is up 31% this year and approximately 28% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gm-in-talks-to-renew-jv-with-chinas-saic-report/chDGDTkRd6t">GM In Talks To Renew JV With China’s SAIC: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Roivant Sciences logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17

Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study, the company said. 

Dave &amp; Buster's Entertainment (PLAY) was among the top five losers on Stocktwits after multiple price target cuts from Wall Street following its second-quarter sales, which were pressured due to a difficult macro environment and challenges related to the brand.Shares of the company were down nearly 17% before the bell on Tuesday after Dave &amp; Buster’s <a href="https://stocktwits.com/news-articles/markets/equity/why-is-dave-and-busters-stock-plunging-premarket/chwyaxsRdyl">missed quarterly results</a>. UBS cut its price target on Dave &amp; Buster's to $25 from $29 and maintained a ‘Neutral’ rating, according to TheFly.The firm said that <a href="https://stocktwits.com/symbol/PLAY">Dave &amp; Buster's</a> second-quarter results included still pressured sales trends, likely given a difficult macro and brand-specific challenges, while margins and earnings were also depressed.UBS noted that while the company is still in the early stages of a turnaround, with macro pressure remaining elevated and visibility limited, an eventual return to consistently positive same-store sales represents potential upside for shares.The retail user message count on the stock jumped 5,200% in the last 24 hours on Stocktwits. Retail sentiment remained unchanged in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<figure class="image"><img style="aspect-ratio:792/102;" src="https://news.stocktwits-cdn.com/PLAY_sentiment_png_f0791affdf.webp" alt="PLAY sentiment.png" width="792" height="102"><figcaption>PLAY sentiment and message volume September 16, 2025, as of 8:10 am ET | Source: Stocktwits</figcaption></figure>Truist Securities cut its price target on Dave &amp; Buster's to $22 from $27 and maintained a ‘Hold’ rating. The firm said that the company's same-store sales decelerated in the back half of the quarter despite much easier year-ago compares as growing macro headwinds offset recent gains from its "back to basics" approach.Brokerage Truist Securities noted that while it sees incremental sales drivers in the second half of 2025, it also sees a risk that consumer pressures mount. Piper Sandler lowered its price target on Dave &amp; Buster's to $26 from $30 and maintained a ‘Neutral’ rating, according to TheFly.A bearish user on Stocktwits noted that there was “no upward catalyst” until the next earnings.<stembedurl>https://stocktwits.com/Bobky2030/message/628801944</stembedurl>Shares of Dave &amp; Buster’s have declined over 17% this year and lost nearly a quarter of its value in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/united-airlines-to-hire-2500-employees-at-newark-airport/chwyLDMRdzb">United Airlines To Hire 2,500 Employees At Newark Airport</a>

The exterior of a Dave & Buster's restaurant is seen on June 10, 2025 in Austin, Texas.

Dave & Buster’s Sees Wall Street Downgrades, Yet Retail Sentiment Red-Hot

UBS said that while Dave & Buster’s was still in the early stages of a turnaround, with macro pressure remaining elevated and visibility limited, an eventual return to consistently positive same-store sales represents potential upside for shares.

In this photo illustration, a smartphone held in a hand shows the logo of The Kroger Co. (NYSE: KR), a U.S. supermarket chain and one of the largest grocery retailers in the country.

Kroger Interim CEO Highlights Shift To Coupons, Private Labels Amid Economic Pressures: ‘Customers Are Feeling Stressed’

However, Ron Sargent also noted that Kroger was adding new households and growing order volumes with existing consumers who already shop with the grocer.

PKW
Invesco BuyBack Achievers ETF

Feed

News

Sentiment

Fundamentals

Info

Latest PKW News

PKWInvesco BuyBack Achievers ETF